UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 2, 2024 (November 27, 2024)
AIMFINITY
INVESTMENT CORP. I
(Exact
name of registrant as specified in its charter)
| Cayman Islands |
|
001-41361 |
|
N/A |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of incorporation) |
|
|
|
Identification Number) |
221 W 9th St, PMB 235
Wilmington, Delaware 19801
(Address
of principal executive offices)
(425) 365-2933
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☒ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act.
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Units, consisting of one
Class A ordinary share, $0.0001 par value, one Class 1 redeemable warrant and one-half of one Class 2 redeemable warrant |
|
AIMAU |
|
The
Nasdaq Stock Market LLC |
| Class A ordinary shares,
$0.0001 par value |
|
AIMA |
|
The
Nasdaq Stock Market LLC |
| Class 1 redeemable warrants,
each exercisable for one Class A ordinary share at an exercise price of $11.50 |
|
AIMAW |
|
The
Nasdaq Stock Market LLC |
| Class 2 redeemable warrants,
each exercisable for one Class A ordinary share at an exercise price of $11.50 |
|
AIMAW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
On
April 23, 2024, Aimfinity Investment Corp. I, a Cayman Islands exempted company (the “Company”), held an extraordinary
general meeting (the “Shareholder Meeting”), where the shareholders of the Company approved to amend the Company’s
amended and restated memorandum and articles of associations (the “Charter”) to allow the Company until April 28,
2024 to consummate an initial business combination and may elect to extend the period to consummate an initial business combination up
to nine times, each by an additional one-month period (each, a “Monthly Extension”), for a total of up to nine months
to January 28, 2025, by depositing to the Company’s trust account (the “Trust Account”) the lesser of (i) $60,000
for all public shares and (ii) $0.035 for each public share for each one-month extension.
On
November 27, 2024, the Company issued an unsecured promissory note of $60,000 (the “Note”) to I-Fa Chang, a member
and manager of Aimfinity Investment LLC, the sponsor of the company (the “Sponsor”), as the Sponsor’s designee, to
evidence the payments made for $60,000 (the “New Monthly Extension Payment”) to the Trust Account for the public shareholders,
which enables the Company to extend the period of time it has to consummate its initial business combination by one month from November
28, 2024 to December 28, 2024 (the “New Extension”). The New Extension is the eighth of the up to nine Monthly Extensions
permitted under the amended Charter.
The
Note bears no interest and is payable in full upon the earlier to occur of (i) the consummation of the Company’s business combination
(the “Business Combination”) or (ii) the date of expiry of the term of the Company (the “Maturity Date”).
The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date;
(ii) the commencement of a voluntary or involuntary bankruptcy action, (iii) the breach of the Company’s obligations thereunder;
(iv) any cross defaults; (v) an enforcement proceedings against the Company; and (vi) any unlawfulness and invalidity in connection with
the performance of the obligations thereunder, in which case the Note may be accelerated.
The
payee of the Note, Mr. Chang, has the right, but not the obligation, to convert the Promissory Note, in whole or in part, respectively,
into private units (the “Private Units”) of the Company, that are identical to The Private Units issued by the Company
in the private placement consummated simultaneously with the Company’s initial public offering, subject to certain exceptions,
as described in the final prospectus of the Company (File Number: 333-263874), by providing the Company with written notice of the intention
to convert at least two business days prior to the closing of the Business Combination. The number of Private Units to be received by
the Sponsor in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount
payable to the Sponsor by (y) $10.00.
The
issuance of the Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933,
as amended.
A
copy of the Note is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The disclosures
set forth in this Item 2.03 are intended to be summaries only and are qualified in their entirety by reference to the Note.
Item
3.02 Unregistered Sales of Equity Securities.
The
information disclosed under Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02 to
the extent required herein. The Private Units (and the underlying securities) issuable upon conversion of the Note, if any, (1) may not,
subject to certain limited exceptions, be transferable or salable by the Sponsor until the completion of the Company’s initial
Business Combination and (2) are entitled to registration rights.
Item
7.01 Regulation FD Disclosure.
On
December 2, 2024, the Company issued a press release (the “Press Release”) announcing that the New Extension. A copy
of the Press Release is furnished as Exhibit 99.1 hereto. The information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act of 1934, both as amended, except as expressly set forth by specific reference in such filing.
IMPORTANT
NOTICES
Important
Notice Regarding Forward-Looking Statements
As
disclosed previously on the Current Report on Form 8-K filed on October 16, 2023, on October 13, 2023, AIMA entered into that certain
Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”),
with Docter Inc., a Delaware corporation (“Docter”), Aimfinity Investment Merger Sub I, a Cayman Islands exempted
company and wholly-owned subsidiary of AIMA (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware
corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”), pursuant to AIMA will enter into a business combination
with Docter that involves a reincorporation merger and an acquisition merger.
This
Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the Securities Act of 1933
and the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements about the pending
transactions described above, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include,
but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing
equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated
future financial and operating performance and results, including estimates for growth, the expected management and governance of the
combined company, and the expected timing of the transactions. The words “expect,” “believe,” “estimate,”
“intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements
are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about
general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially
from those indicated or anticipated.
Such
risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the
pending business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction
not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental
entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations
or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the
businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable
transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance,
operations or prospects of Docter or AIMA; (v) risks related to disruption of management time from ongoing business operations due to
the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the
market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect
on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers
and on their operating results and businesses generally; (viii): risks relating to the medical device industry, including but not limited
to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating
to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base
and maintain stable relationship with its business partners. A further list and description of risks and uncertainties can be found in
the prospectus filed on April 26, 2022 relating to AIMA’s initial public offering (the “IPO Prospectus”), the
annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2022, filed on April 17, 2023 (the “Annual Report”),
and in the registration statement on Form S-4 or Form F-4/proxy statement that will be filed with the SEC by Purchaser in connection
with the proposed transactions, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may
vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue
reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and AIMA, Docter and
their subsidiaries undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they
were made except as required by law or applicable regulation.
Additional
Information and Where to Find It
In
connection with the transaction described herein, Purchaser will file relevant materials with the SEC including the registration statement
on Form S-4 or Form F-4 and a proxy statement (the “Registration Statement”). The proxy statement and a proxy card
will be mailed to shareholders as of a record date to be established for voting at the stockholders’ meeting of Parent shareholders
relating to the proposed transactions. Shareholders will also be able to obtain a copy of the Registration Statement and proxy statement
without charge from Parent. The Registration Statement and proxy statement, once available, may also be obtained without charge at the
SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF PARENT ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS
OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTIONS THAT PARENT WILL FILE WITH THE SEC WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PARENT, THE COMPANY AND THE TRANSACTIONS DESCRIBED HEREIN.
Participants
in Solicitation
AIMA,
Docter, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation
of proxies from the holders of AIMA’s ordinary shares stock in respect of the proposed transaction. Information about AIMA’s
directors and executive officers and their ownership of AIMA ordinary shares is set forth in the IPO Prospectus and the Annual Report.
Other information regarding the interests of the participants in the proxy solicitation will be included in the proxy statement pertaining
to the proposed transaction when it becomes available. These documents can be obtained free of charge from the sources indicated above.
No
Offer or Solicitation
This
Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities
or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the
securities of AIMA or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation,
or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering
of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as
amended, or an exemption therefrom.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Aimfinity Investment Corp. I |
| |
|
| |
By: |
/s/
I-Fa Chang |
| |
Name: |
I-Fa Chang |
| |
Title: |
Chief Executive Officer |
| |
|
|
| Date: December 2, 2024 |
|
|
4
Exhibit 10.1
THIS
PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”).
THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE
THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED.
PROMISSORY
NOTE
Principal
Amount: US$60,000
Dated:
November 27, 2024
New
York, New York
FOR
VALUE RECEIVED, Aimfinity Investment Corp. I (the “Maker” or the “Company”) promises to pay
to the order of I-Fa Chang, a member and the manager of Aimfinity Investment LLC, or his assignees or successors in interest (the
“Payee”), the principal sum of Sixty Thousand Dollars (US$60,000), on the terms and conditions described below. All
payments on this Note shall be made by wire transfer of immediately available funds to such account as the Payee may from time to time
designate by written notice in accordance with the provisions of this note (the “Note”).
| 1. | Principal.
The principal balance of this Note shall be payable by the Maker to the Payee upon the
date on which the Maker consummates a business combination or merger with a qualified target
company (as described in its Prospectus (as defined below)) (a “Business Combination”)
or the date of expiry of the term of the Maker, whichever is earlier (such date, the “Maturity
Date”). The principal balance may be prepaid at any time prior to the Maturity
Date without penalty. Under no circumstances shall any individual, including but not limited
to any officer, director, employee or stockholder of the Maker, be obligated personally for
any obligations or liabilities of the Maker hereunder. |
| 2. | Conversion
Rights. The Payee has the right, but not the obligation, to convert this Note, in whole
or in part, into private units (the “Units”) of the Maker, each consisting
of one Class A ordinary share, one Class 1 redeemable warrant and one-half of one Class 2
redeemable warrant, as described in the Prospectus of the Maker (File Number 333-263874)
(the “Prospectus”), by providing the Maker with written notice of its
intention to convert this Note at least two business days prior to the closing of a Business
Combination. The number of Units to be received by the Payee in connection with such conversion
shall be an amount determined by dividing (x) the sum of the outstanding principal amount
payable to such Payee by (y) $10.00. |
| (a) | Fractional
Units. No fractional Units will be issued upon conversion of this Note. In lieu of any
fractional Units to which Payee would otherwise be entitled, the Maker will pay to Payee
in cash the amount of the unconverted principal balance of this Note that would otherwise
be converted into such fractional Units. |
| (b) | Effect
of Conversion. If the Maker timely receives notice of the Payee’s intention to
convert this Note at least two business days prior to the closing of a Business Combination,
this Note shall be deemed to be converted on such closing date. At its expense, the Maker
will, upon receipt of such conversion notice, as soon as practicable after consummation of
a Business Combination, issue and deliver to Payee, at Payee’s address as requested
by Payee in its conversion notice, a certificate or certificates for the number of Units
to which Payee is entitled upon such conversion (bearing such legends as are customary pursuant
to applicable state and federal securities laws), including a check payable to Payee for
any cash amounts payable as a result of any fractional Units as described herein. |
| 3. | Interest.
This Note does not carry any interest on the unpaid principal balance of this Note, provided,
that, any overdue amounts shall accrue default interest at a rate per annum equal to the
interest rate which is the prevailing short term United States Treasury Bill rate, from the
date on which such payment is due until the day on which all sums due are received by the
Payee. |
| 4. | Application
of Payments. All payments shall be applied first to payment in full of any costs incurred
in the collection of any sum due under this Note, including but not limited to reasonable
attorney’s and auditor’s fees and expenses, then to the payment in full of any
late charges, and finally to the reduction of the unpaid principal balance of this Note. |
| 5. | Events
of Default. The following shall constitute an event of default (each, an “Event
of Default”): |
| (a) | Failure
to Make Required Payments. Failure by the Maker to pay the principal amount due pursuant
to this Note more than 5 business days of the Maturity Date. |
| (b) | Voluntary
Bankruptcy, etc. The commencement by the Maker of a voluntary case under any applicable
bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent
by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee,
custodian, sequestrator (or other similar official) of the Maker or for any substantial part
of its property, or the making by it of any assignment for the benefit of creditors, or the
failure of the Maker generally to pay its debts as such debts become due, or the taking of
corporate action by the Maker in furtherance of any of the foregoing. |
| (c) | Involuntary
Bankruptcy, etc. The entry of a decree or order for relief by a court having jurisdiction
in the premises in respect of the Maker in an involuntary case under any applicable bankruptcy,
insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian,
trustee, sequestrator (or similar official) of the Maker or for any substantial part of its
property, or ordering the winding-up or liquidation of its affairs, and the continuance of
any such decree or order unstayed and in effect for a period of 60 consecutive days. |
| (d) | Breach
of Other Obligations. The Maker fails to perform or comply with any one or more of its
obligations under this Note. |
| (e) | Cross
Default. Any present or future indebtedness of the Maker in respect of moneys borrowed
or raised becomes (or becomes capable of being declared) due and payable prior to its stated
maturity by reason of any event of default, or any such indebtedness is not paid when due
or, as the case may be, within any applicable grace period. |
| (f) | Enforcement
Proceedings. A distress, attachment, execution or other legal process is levied or enforced
on or against any assets of the Maker which is not discharged or stayed within 30 days. |
| (g) | Unlawfulness
and Invalidity. It is or becomes unlawful for the Maker to perform any of its obligations
under this Note, or any obligations of the Maker under this Note are not or cease to be legal,
valid, binding or enforceable. |
| (a) | Upon
the occurrence of an Event of Default specified in Section 5(a) and 5(d) hereof, the Payee
may, by written notice to the Maker, declare this Note to be due immediately and payable,
whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder,
shall become immediately due and payable without presentment, demand, protest or other notice
of any kind, all of which are hereby expressly waived, notwithstanding anything contained
herein or in the documents evidencing the same to the contrary. |
| (b) | Upon
the occurrence of an Event of Default specified in Sections 5(b), 5(c), 5(e), 5(f) and 5(g)
hereof, the unpaid principal balance of this Note, and all other sums payable with regard
to this Note hereunder, shall automatically and immediately become due and payable, in all
cases without any action on the part of the Payee. |
| 7. | Taxes.
The Maker will pay all amounts due hereunder free and clear of and without reduction
for any taxes, levies, imposts, deductions, withholding or charges imposed or levied by any
governmental authority or any political subdivision or taxing authority thereof with respect
thereto (“Taxes”). The Maker will pay on behalf of the Payee all such
Taxes so imposed or levied and any additional amounts as may be necessary so that the net
payment of principal and any interest on this Note received by the Payee after payment of
all such Taxes shall be not less than the full amount provided hereunder. |
| 8. | Waivers.
The Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment
for payment, demand, notice of dishonor, protest, and notice of protest with regard to the
Note, all errors, defects and imperfections in any proceedings instituted by the Payee under
the terms of this Note, and all benefits that might accrue to the Maker by virtue of any
present or future laws exempting any property, real or personal, or any part of the proceeds
arising from any sale of any such property, from attachment, levy or sale under execution,
or providing for any stay of execution, exemption from civil process, or extension of time
for payment; and the Maker agrees that any real estate that may be levied upon pursuant to
a judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold
upon any such writ in whole or in part in any order desired by the Payee. |
| 9. | Unconditional
Liability. The Maker hereby waives all notices in connection with the delivery, acceptance,
performance, default, or enforcement of the payment of this Note, and agrees that its liability
shall be unconditional, without regard to the liability of any other party, and shall not
be affected in any manner by any indulgence, extension of time, renewal, waiver or modification
granted or consented to by the Payee, and consents to any and all extensions of time, renewals,
waivers, or modifications that may be granted by the Payee with respect to the payment or
other provisions of this Note, and agrees that additional makers, endorsers, guarantors,
or sureties may become parties hereto without notice to the Maker or affecting the Maker’s
liability hereunder. For the purpose of this Note, “business day” shall mean
a day (other than a Saturday, Sunday or public holiday) on which banks are open in China
and New York for general banking business. |
| 10. | Notices.
All notices, statements or other documents which are required or contemplated by this
Note shall be made in writing and delivered: (i) personally or sent by first class registered
or certified mail, overnight courier service to the address most recently provided in writing
to such party or such other address as may be designated in writing by such party, (ii) by
fax to the number most recently provided to such party or such other fax number as may be
designated in writing by such party, or (iii) by email, to the email address most recently
provided to such party or such other email address as may be designated in writing by such
party. Any notice or other communication so transmitted shall be deemed to have been given
on (a) the day of delivery, if delivered personally, (b) only if the receipt is acknowledged,
the day after such receipt, if sent by fax or email, (c) the business day after delivery
to an overnight courier service, if sent by an overnight courier service, or (d) 5 days after
mailing if sent by first class registered or certified mail. |
| 11. | Construction.
This Note shall be construed and enforced in accordance with the laws of New York, without
regard to conflict of law provisions thereof. |
| 12. | Severability.
Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability
without invalidating the remaining provisions hereof, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other
jurisdiction. The Payee hereby waives any and all right, title, interest or claim of any
kind (“Claim”) in or to any amounts contained in the trust account deriving
from the proceeds of the IPO conducted by the Maker and the proceeds of the sale of securities
in a private placement (if any) prior to the effectiveness of the IPO, as described in greater
detail in the Prospectus filed with the Securities and Exchange Commission in connection
with the IPO (the “Trust Account Funds”), and hereby agrees not to seek
recourse, reimbursement, payment or satisfaction for any Claim from the Trust Account Funds
or any distribution therefrom for any reason whatsoever. If Maker does not consummate the
Business Combination, this Note shall be repaid only from amounts other than Trust Account
Funds, if any. |
| 13. | Amendment;
Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and
only with, the written consent of the Maker and the Payee. |
| 14. | Assignment.
This Note shall be binding upon the Maker and its successors and assigns and is for the
benefit of the Payee and its successors and assigns, except that the Maker may not assign
or otherwise transfer its rights or obligations under this Note. The Payee may at any time
without the consent of or notice to the Maker assign to one or more entities all or a portion
of its rights under this Note. |
[signature
page follows]
The
Parties, intending to be legally bound hereby, have caused this Note to be duly executed by the undersigned as of the day and year first
above written.
MAKER:
Aimfinity
Investment Corp. I
| By: |
/s/ I-Fa Chang |
|
| Name: |
I-Fa Chang |
|
| Title: |
CEO and Chairman |
|
PAYEE:
I-Fa
Chang
[signature
page to the promissory note]
Exhibit
99.1
Aimfinity
Investment Corp. I Announces Extension of the Deadline for an Initial Business Combination to December 28, 2024
Wilmington, Delaware, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (the “Company” or “AIMA”) (Nasdaq:
AIMAU), a special purpose acquisition company incorporated as a Cayman Islands exempted company, today announced that, in order to extend
the date by which the Company mush complete its initial business combination from November 28, 2024 to December 28, 2024, I-Fa Chang,
manager of the sponsor of the Company, has deposited into its trust account (the “Trust Account”) an aggregate of $60,000
(the “Monthly Extension Payment”) on November 27, 2024.
Pursuant
to the Company’s third amended & restated memorandum and articles of association (“Current Charter”), effectively
April 23, 2024, the Company may extend on a monthly basis from April 28, 2024 until January 28, 2025 or such an earlier date as may be
determined by its board to complete a business combination by depositing the Monthly Extension Payment for each month into the Trust
Account. This is the eighth of nine monthly extensions sought under the Current Charter of the Company.
About
Aimfinity Investment Corp. I
Aimfinity
Investment Corp. I is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
The Company has not selected any business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions,
directly or indirectly, with any business combination target with respect to an initial business combination with it. While the Company
will not be limited to a particular industry or geographic region in its identification and acquisition of a target company, it will
not complete its initial business combination with a target that is headquartered in China (including Hong Kong and Macau) or conducts
a majority of its business in China (including Hong Kong and Macau).
Additional
Information and Where to Find It
As
previously disclosed, on October 13, 2023, the Company entered into that certain Agreement and Plan of Merger (as may be amended, supplemented
or otherwise modified from time to time, the “Merger Agreement”), by and between the Company, Docter Inc., a Delaware corporation
(the “Company”), Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of Parent
(“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser
(“Merger Sub”), pursuant to which the Company is proposing to enter into a business combination with Docter involving an
reincorporation merger and an acquisition merger. This press release does not contain all the information that should be considered concerning
the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of
the business combination. AIMA’s stockholders and other interested persons are advised to read, when available, the proxy statement/prospectus
and the amendments thereto and other documents filed in connection with the proposed business combination, as these materials will contain
important information about AIMA, Purchaser or Docter, and the proposed business combination. When available, the proxy statement/prospectus
and other relevant materials for the proposed business combination will be mailed to stockholders of AIMA as of a record date to be established
for voting on the proposed business combination. Such stockholders will also be able to obtain copies of the proxy statement/prospectus
and other documents filed with the Securities and Exchange Commission (the “SEC”), without charge, once available, at the
SEC’s website at www.sec.gov, or by directing a request to AIMA’s principal office at 221 W 9th St, PMB 235 Wilmington,
Delaware 19801.
Forward-Looking
Statements
This
press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements about the pending transactions
described herein, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but
are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing
equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated
future financial and operating performance and results, including estimates for growth, the expected management and governance of the
combined company, and the expected timing of the transactions. The words “expect,” “believe,” “estimate,”
“intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements
are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about
general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially
from those indicated or anticipated.
Such
risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the
pending business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction
not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental
entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations
or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the
businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable
transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance,
operations or prospects of AIMA or Docter; (v) risks related to disruption of management time from ongoing business operations due to
the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the
market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect
on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers
and on their operating results and businesses generally; (viii): risks relating to the medical device industry, including but not limited
to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating
to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base
and maintain stable relationship with its business partners.
A
further list and description of risks and uncertainties can be found in the prospectus filed on April 26, 2022 relating to AIMA’s
initial public offering, the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2022, filed on April 17, 2023,
and in the Registration Statement/proxy statement that will be filed with the SEC by AIMA and/or its affiliates in connection with the
proposed transactions, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should
one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially
from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on
these forward-looking statements. Forward-looking statements relate only to the date they were made, and Aimfinity, Docter, and their
subsidiaries undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were
made except as required by law or applicable regulation.
No
Offer or Solicitation
This
press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect
of any potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of AIMA, Purchaser
or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the requirements of the Securities Act.
Participants
in the Solicitation
AIMA,
Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed
to be participants in the solicitation of proxies of AIMA’s shareholders in connection with the proposed transaction. Information
regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection
with the proposed business combination will be set forth in the proxy statement/prospectus on Form F-4 to be filed with the SEC.
Contact Information:
Aimfinity
Investment Corp. I
I-Fa Chang
Chief Executive Officer
(425) 365-2933
221 W 9th St, PMB 235
Wilmington, Delaware 19801
Aimfinity Investment Cor... (NASDAQ:AIMBU)
過去 株価チャート
から 12 2024 まで 1 2025
Aimfinity Investment Cor... (NASDAQ:AIMBU)
過去 株価チャート
から 1 2024 まで 1 2025
